Optimizing the Use of Cabotegravir Plus Rilpivirine Long-acting Therapy in HIV Care: Evidence, Implementation, and Unanswered Questions

Anna Maria Geretti; Marta Boffito; Stefano Bonora; Patrick Braun; Charlotte Charpentier; Federico Garcia; Jade Ghosn; Perpetua Gomes; Anne Geneviève Marcelin; Thibault Mesplède; Milosz Parczewski; Kyle Ring; Maria Mercedes Santoro; Caroline Solas; Eva Wolf; Chloe Orkin

doi:10.1093/ofid/ofaf368

Optimizing the Use of Cabotegravir Plus Rilpivirine Long-acting Therapy in HIV Care: Evidence, Implementation, and Unanswered Questions

Anna Maria Geretti
, Marta Boffito
, Stefano Bonora
, Patrick Braun
, Charlotte Charpentier
, Federico Garcia
, Jade Ghosn
, Perpetua Gomes
, Anne Geneviève Marcelin
, Thibault Mesplède
, Milosz Parczewski
, Kyle Ring
, Maria Mercedes Santoro
, Caroline Solas
, Eva Wolf
, Chloe Orkin

Research output: Contribution to journal › Review article › peer-review

4 Citations (Scopus)

Abstract

Cabotegravir plus rilpivirine long-acting (CAB + RPV-LA) injectable therapy marks a major milestone in HIV care, offering an efficacious, well-tolerated alternative to daily oral antiretroviral treatment. This article reviews data from pivotal trials and observational studies of CAB + RPV-LA, addressing emerging questions and highlighting key research priorities. We examine factors influencing virological outcomes, including issues related to HIV subtype, archived drug resistance, body mass index, and pharmacokinetics, and discuss challenges related to hepatitis B virus immunity and infection, pregnancy, and adherence. We outline strategies to address barriers to implementation, advocating for a tailored approach to maximize the potential of CAB + RPV-LA in improving outcomes across diverse populations with HIV.

Original language	English
Article number	ofaf368
Journal	Open Forum Infectious Diseases
Volume	12
Issue number	7
DOIs	https://doi.org/10.1093/ofid/ofaf368
Publication status	Published - 1 Jul 2025

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

HBV
long-acting
pharmacokinetics
resistance
subtype

Access to Document

10.1093/ofid/ofaf368

Cite this

Geretti, A. M., Boffito, M., Bonora, S., Braun, P., Charpentier, C., Garcia, F., Ghosn, J., Gomes, P., Marcelin, A. G., Mesplède, T., Parczewski, M., Ring, K., Santoro, M. M., Solas, C., Wolf, E., & Orkin, C. (2025). Optimizing the Use of Cabotegravir Plus Rilpivirine Long-acting Therapy in HIV Care: Evidence, Implementation, and Unanswered Questions. Open Forum Infectious Diseases, 12(7), Article ofaf368. https://doi.org/10.1093/ofid/ofaf368

@article{8905c2fdc1b8473e80a9d08c59afcbca,

title = "Optimizing the Use of Cabotegravir Plus Rilpivirine Long-acting Therapy in HIV Care: Evidence, Implementation, and Unanswered Questions",

abstract = "Cabotegravir plus rilpivirine long-acting (CAB + RPV-LA) injectable therapy marks a major milestone in HIV care, offering an efficacious, well-tolerated alternative to daily oral antiretroviral treatment. This article reviews data from pivotal trials and observational studies of CAB + RPV-LA, addressing emerging questions and highlighting key research priorities. We examine factors influencing virological outcomes, including issues related to HIV subtype, archived drug resistance, body mass index, and pharmacokinetics, and discuss challenges related to hepatitis B virus immunity and infection, pregnancy, and adherence. We outline strategies to address barriers to implementation, advocating for a tailored approach to maximize the potential of CAB + RPV-LA in improving outcomes across diverse populations with HIV.",

keywords = "HBV, long-acting, pharmacokinetics, resistance, subtype",

author = "Geretti, \{Anna Maria\} and Marta Boffito and Stefano Bonora and Patrick Braun and Charlotte Charpentier and Federico Garcia and Jade Ghosn and Perpetua Gomes and Marcelin, \{Anne Genevi{\`e}ve\} and Thibault Mespl{\`e}de and Milosz Parczewski and Kyle Ring and Santoro, \{Maria Mercedes\} and Caroline Solas and Eva Wolf and Chloe Orkin",

note = "Publisher Copyright: {\textcopyright} 2025 The Author(s). ",

year = "2025",

month = jul,

day = "1",

doi = "10.1093/ofid/ofaf368",

language = "English",

volume = "12",

journal = "Open Forum Infectious Diseases",

issn = "2328-8957",

publisher = "Oxford University Press",

number = "7",

}

Geretti, AM, Boffito, M, Bonora, S, Braun, P, Charpentier, C, Garcia, F, Ghosn, J, Gomes, P, Marcelin, AG, Mesplède, T, Parczewski, M, Ring, K, Santoro, MM, Solas, C, Wolf, E & Orkin, C 2025, 'Optimizing the Use of Cabotegravir Plus Rilpivirine Long-acting Therapy in HIV Care: Evidence, Implementation, and Unanswered Questions', Open Forum Infectious Diseases, vol. 12, no. 7, ofaf368. https://doi.org/10.1093/ofid/ofaf368

TY - JOUR

T1 - Optimizing the Use of Cabotegravir Plus Rilpivirine Long-acting Therapy in HIV Care

T2 - Evidence, Implementation, and Unanswered Questions

AU - Geretti, Anna Maria

AU - Boffito, Marta

AU - Bonora, Stefano

AU - Braun, Patrick

AU - Charpentier, Charlotte

AU - Garcia, Federico

AU - Ghosn, Jade

AU - Gomes, Perpetua

AU - Marcelin, Anne Geneviève

AU - Mesplède, Thibault

AU - Parczewski, Milosz

AU - Ring, Kyle

AU - Santoro, Maria Mercedes

AU - Solas, Caroline

AU - Wolf, Eva

AU - Orkin, Chloe

PY - 2025/7/1

Y1 - 2025/7/1

N2 - Cabotegravir plus rilpivirine long-acting (CAB + RPV-LA) injectable therapy marks a major milestone in HIV care, offering an efficacious, well-tolerated alternative to daily oral antiretroviral treatment. This article reviews data from pivotal trials and observational studies of CAB + RPV-LA, addressing emerging questions and highlighting key research priorities. We examine factors influencing virological outcomes, including issues related to HIV subtype, archived drug resistance, body mass index, and pharmacokinetics, and discuss challenges related to hepatitis B virus immunity and infection, pregnancy, and adherence. We outline strategies to address barriers to implementation, advocating for a tailored approach to maximize the potential of CAB + RPV-LA in improving outcomes across diverse populations with HIV.

AB - Cabotegravir plus rilpivirine long-acting (CAB + RPV-LA) injectable therapy marks a major milestone in HIV care, offering an efficacious, well-tolerated alternative to daily oral antiretroviral treatment. This article reviews data from pivotal trials and observational studies of CAB + RPV-LA, addressing emerging questions and highlighting key research priorities. We examine factors influencing virological outcomes, including issues related to HIV subtype, archived drug resistance, body mass index, and pharmacokinetics, and discuss challenges related to hepatitis B virus immunity and infection, pregnancy, and adherence. We outline strategies to address barriers to implementation, advocating for a tailored approach to maximize the potential of CAB + RPV-LA in improving outcomes across diverse populations with HIV.

KW - HBV

KW - long-acting

KW - pharmacokinetics

KW - resistance

KW - subtype

UR - https://www.scopus.com/pages/publications/105012388995

U2 - 10.1093/ofid/ofaf368

DO - 10.1093/ofid/ofaf368

M3 - Review article

C2 - 40735332

AN - SCOPUS:105012388995

SN - 2328-8957

VL - 12

JO - Open Forum Infectious Diseases

JF - Open Forum Infectious Diseases

IS - 7

M1 - ofaf368

ER -

Optimizing the Use of Cabotegravir Plus Rilpivirine Long-acting Therapy in HIV Care: Evidence, Implementation, and Unanswered Questions

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this